John Pei-wen Chiang1, Karmen Trzupek. 1. aCasey Eye Institute Molecular Diagnostic laboratory, OHSU, Portland, Oregon bInformedDNA, St. Petersburg, Florida, USA.
Abstract
PURPOSE OF REVIEW: We are witnessing lightning-fast advances in the molecular diagnosis of inherited retinal dystrophies, mainly due to the widespread use of next-generation sequencing technologies. The purpose of this review is to highlight the breadth of findings from this in-depth testing approach, and to propose changes to our traditional testing and diagnostic paradigms. Lessons learned from modern molecular testing suggest that the previous concept of inherited retinal dystrophies as a group of 'single gene diseases' may require a significant update. RECENT FINDINGS: All of the known retinal dystrophies genes can now be sequenced. In many cases, this nonhypothesis driven testing strategy is uncovering mutations in unsuspected genes, generating data that challenges established concepts of genetic mechanisms and provides insights regarding genes previously thought to be exclusively related to syndromic disease. Recent advances in testing have improved not only the breadth, but also the depth of genetic data. For example, deep intronic sequencing has uncovered many novel intronic mutations/variations in the ABCA4 gene. SUMMARY: Currently, in approximately 50-60% of patients with nonsyndromic retinal dystrophy, the disease mechanism can be identified. The presence of pathogenic alleles in more than one gene is not uncommon. Retinal dystrophy, with relatively defined clinical presentations and a large but limited number of genes involved, is becoming a model for the next-generation study of molecular disease mechanisms.
PURPOSE OF REVIEW: We are witnessing lightning-fast advances in the molecular diagnosis of inherited retinal dystrophies, mainly due to the widespread use of next-generation sequencing technologies. The purpose of this review is to highlight the breadth of findings from this in-depth testing approach, and to propose changes to our traditional testing and diagnostic paradigms. Lessons learned from modern molecular testing suggest that the previous concept of inherited retinal dystrophies as a group of 'single gene diseases' may require a significant update. RECENT FINDINGS: All of the known retinal dystrophies genes can now be sequenced. In many cases, this nonhypothesis driven testing strategy is uncovering mutations in unsuspected genes, generating data that challenges established concepts of genetic mechanisms and provides insights regarding genes previously thought to be exclusively related to syndromic disease. Recent advances in testing have improved not only the breadth, but also the depth of genetic data. For example, deep intronic sequencing has uncovered many novel intronic mutations/variations in the ABCA4 gene. SUMMARY: Currently, in approximately 50-60% of patients with nonsyndromic retinal dystrophy, the disease mechanism can be identified. The presence of pathogenic alleles in more than one gene is not uncommon. Retinal dystrophy, with relatively defined clinical presentations and a large but limited number of genes involved, is becoming a model for the next-generation study of molecular disease mechanisms.
Authors: Hema L Ramkumar; Harini V Gudiseva; Kameron T Kishaba; John J Suk; Rohan Verma; Keerti Tadimeti; John A Thorson; Radha Ayyagari Journal: Genet Test Mol Biomarkers Date: 2016-12-22
Authors: Charles J Wolock; Nicholas Stong; Chu Jian Ma; Takayuki Nagasaki; Winston Lee; Stephen H Tsang; Sitharthan Kamalakaran; David B Goldstein; Rando Allikmets Journal: Genet Med Date: 2019-03-30 Impact factor: 8.822
Authors: G Jane Farrar; Matthew Carrigan; Adrian Dockery; Sophia Millington-Ward; Arpad Palfi; Naomi Chadderton; Marian Humphries; Anna Sophia Kiang; Paul F Kenna; Pete Humphries Journal: Hum Mol Genet Date: 2017-08-01 Impact factor: 6.150
Authors: Jinu Han; John Hoon Rim; In Sik Hwang; Jieun Kim; Saeam Shin; Seung-Tae Lee; Jong Rak Choi Journal: Mol Vis Date: 2017-09-20 Impact factor: 2.367